Neovacs SA (FR:ALNEV) has released an update.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Neovacs SA, a French biotech firm specializing in inflammatory and autoimmune therapies, has disclosed its share capital composition, revealing a total of 347,174,292 shares and equal voting rights as of August 31, 2024. The company has undergone a share consolidation and issues monthly reports on new share creation, including conversions of OCEANE bonds and exercises of BSA E, with detailed updates available on its website. However, the company warns of potential share price volatility and investor dilution due to the rapid sale of shares by the European High Growth Opportunities Securitization Fund and a trust responsible for the equitization of ORA financing.
For further insights into FR:ALNEV stock, check out TipRanks’ Stock Analysis page.